Taxiarchis Kourelis

1 month ago | nature.com | Moritz Binder |Joselle M. Cook |Prashant Kapoor |Taxiarchis Kourelis |Shaji Kumar |Mustaqeem Siddiqui | +1 more

AbstractChanges in metabolic activity in tumor cells is one of the hallmarks of cancer. Cancer cells exhibit the Warburg effect with high glucose consumption for their energy needs. This provides the basis for imaging using 18F-2-deoxy-D-glucose for positron emission tomography to assess tumor burden and response to therapy.

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.